TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Uric Acid in Essential Hypertension in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Males or females 12 to 18 years in age.~SBP or DBP greater than 95th percentile for age, gender and height~Diagnosis of primary hypertension after initial workup~No pharmacological therapy for hypertension in the past 12 months~Females must have a negative urine pregnancy test.~Parental or guardian consent and child subject assent~Exclusion Criteria:~Severe or poorly controlled hypertension as defined by SBP or DBP more than 20mmHg \>95th percentile for age, gender and height or a history of hypertensive encephalopathy~Identified cause of secondary hypertension Renal transplant~Taking a calcineurin inhibitor, azathioprine or another nucleoside analogue medication (These medications have potentially serious drug interactions with Allopurinol.)~Currently receiving antihypertensive medication(s) or diuretic(s)~Laboratory abnormalities that indicate clinically significant hematologic, hepatobiliary or renal disease (These abnormalities would be expected to alter drug metabolism and increase the likelihood of medication side effects.):~Schwartz Formula GFR less than 60ml/min/1.73m2, AST/SGOT greater than 2 times the upper limit of normal\* ALT/SGPT greater than 2 times the upper limit of normal\* Total or direct bilirubin more than 2 times the upper limit of normal\* Hemoglobin less than 9 gm/dl WBC less than 3.000/mm3 Platelet count less than 100,000/mm3 \*age-adjusted normal range

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Allopurinol (Type: EXPERIMENTAL): Hypertensive children received both placebo and allopurinol in a cross over design.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Female subject of non-childbearing potential or of childbearing potential agreeing not to become pregnant during the study.~* Have had seasonal allergic rhinitis due to Ragweed for the last 2 consecutive years~* Subjects who obtain a minimum sum considering SAR related symptoms (mean value) as defined by protocol~Exclusion Criteria:~* Any clinically significant condition that might interfere with the treatment evaluation, both for efficacy and safety~* Have used forbidden concomitant medications as defined by the protocol

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (PBO) (Type: PLACEBO_COMPARATOR): A single dose of placebo was administered orally on Day 1.
- Levocetirizine (LCTZ) 2.5 mg (Type: EXPERIMENTAL): A single dose of 2.5 mg of LCTZ oral drops was administered orally on Day 1.
- Levocetirizine (LCTZ) 5 mg (Type: EXPERIMENTAL): A single dose of 5 mg of LCTZ oral tablet was administered orally on Day 1.
- Cetirizine (CTZ) 5 mg (Type: EXPERIMENTAL): A single dose of 5 mg of CTZ oral drops was administered orally on Day 1.
- Cetirizine (CTZ) 10 mg (Type: EXPERIMENTAL): A single dose of 10 mg of CTZ oral tablet was administered orally on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with an acute myocardial infarction with ST elevation~* Subject with an acute myocardial infarction without ST elevation~* Subject with unstable angina (progressive angina during past 2 weeks, negative cardiac markers, Trop T \< 0,014μg/l~* First time of taking Brilique~* ≥ 18 years~* Possibility to take a blood sample before administration of Brilique~* Signed Informed Consent, signed by subject or authorized representative, able and willing to provide written informed consent for study participation~Exclusion Criteria:~* Active haemorrhage~* Moderate or severe liver failure with coagulopathy~* Pregnancy and lactation~* A history of an intra cerebral haemorrhage~* Patient is HIV positive and treated with Ritonavir and /or Atazanavir~* Patient treated with vitamin K antagonist or with a new oral anti coagulant~* Hypersensitivity to ticagrelor or any of the excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- starting with ticagrelor (Type: OTHER): Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Positive qualitative hepatitis C virus RNA test on two occasions at least 6 months apart~* Positive human immunodeficiency virus test~Exclusion Criteria:~* Heart rate \< 50/min,~* Taking amiodarone~* Renal failure

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- sofosbuvir/daclatasvir (Type: EXPERIMENTAL): Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Physician diagnosis of asthma of moderate severity~2. Subjects ≥ 18 years of age~3. Currently receiving an inhaled corticosteroid medication and being prescribed Dulera 100/5 as part of standard of care based upon asthma severity and dosing guidelines~4. Asthma Control Questionnaire (ACQ) result \> 1.0 at entry~5. Demonstration of correct inhalation technique for use of meter-dosed inhalers (MDIs)~6. History of reversible airway obstruction documented by treating physician Exclusion Criteria: intermittent asthma; emphysema, chronic obstructive pulmonary disease; chronic bronchitis; cystic fibrosis; medication that may have a drug interaction with Dulera~Exclusion Criteria~1. Intermittent asthma (asthma exacerbations or symptoms \< 3 days/week)~2. Diagnosis of emphysema in prior year~3. Diagnosis at any time of: chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, bronchiectasis, Churg Strauss, Wegener's, sarcoidosis, pulmonary hypertension or lung cancer~4. On any medication documented to have a drug interaction with Dulera

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulera adherence monitoring (Type: EXPERIMENTAL): Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
- Dulera Standard of Asthma Care (Type: ACTIVE_COMPARATOR): Dulera standard of asthma care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Test of Discomfort and Malaise of Two Different Urine Catheters in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Male~* signed informed Consent,~* Neg. urine multistix~Exclusion Criteria:~* Abnormalities,~* diseases or surgical procedures performed in the lower urinary-tract

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Monza (Type: EXPERIMENTAL): nonCE marked intermittent catheter
- control (Type: ACTIVE_COMPARATOR): SpeediCath coated catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years or older~* With diagnosis of dysfunctional uterine bleeding without organic pathology~* And with at least one of the following symptoms: prolonged, frequent, or excessive bleeding~Exclusion Criteria:~* The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study.~* Women with history of endometrial ablation or dilatation or curettage within 2 months prior to study start will be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) (Type: EXPERIMENTAL): A blister card consists of 28 pills taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to be taken orally daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent given by patient.~2. Male or female patients between 18 and 65 years of age inclusive.~3. Persistent stable asthmatics (FEV1 \> 60%)~4. On ≤ 1000 µg FP or equivalent or if on combination therapy up to 500 µg of FP or equivalent (e.g. FP/SM 125 2-puffs BD or BUD/FM 200/6 2-puffs BD)~5. Patients suffering from stable, persistent, mild to moderate asthma as defined by GINA Guidelines and for whom FEV1 \> 60 %~6. In the opinion of the investigator, able and willing to comply with the requirements of the protocol.~Exclusion Criteria:~1. Severe asthmatics as defined by an FEV1 \< 60% or PEF variability \>30% or with continual daytime or nocturnal symptoms.~2. Known or suspected hypersensitivity to FP or any other constituents of the Test or Reference pMDI~3. Any clinically significant medical condition or abnormality, which, in the opinion of the investigator, might compromise the safety of the patient or which might interfere with the study (such as unstable angina, acute myocardial infarction in the preceding 3 months, recent TIA / CVA).~4. Females who are pregnant, lactating or planning to become pregnant.~5. Approximately half of the subjects will be smokers and half currently non-smokers (or who have ceased smoking at least 1 year previously).~6. Clinically significant laboratory values, as judged by the investigator.~7. Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to the screening visit.~8. Patients who are scheduled to receive any other investigational drug during the course of the study.~9. Concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial.~10. Exacerbations of asthma requiring oral steroids, hospitalisation or change in asthma therapy in the previous three months.~11. Respiratory tract infection in the previous 2 months.~12. Patients with significant concomitant respiratory disease such as COPD, CF, ABPA, active pulmonary TB or bronchiectesis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1: fluticasone/salmeterol (Type: EXPERIMENTAL): 2 puffs twice a day for 2 weeks
- 2: fluticasone (Type: ACTIVE_COMPARATOR): 2 puffs twice a day for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Survey Study - Sensitivity Comparison Between MelaFind and Physician Group

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Board Certified physicians or equivalent~Exclusion Criteria:~* Did not participate in EOS Protocols 20061 or 20081

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- All Dermatologists (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years.~* HIV-1/2 infected patients with Pulmonary TB. This includes sputum smear positive disease.~* Initially smear negative but Xpert-MTB positive or LPA positive taken as a surrogate marker for culture positivity (e.g. miliary TB, Mediastinal adenitis and Chest x-ray with persistent abnormality after antibiotics). as BACTEC (Becton-Dickinson) has been phased out ,Final inclusion will only be patients positive by LJ culture~* Persistent X-ray abnormality will be included for allocation. However final inclusion into both ITT and efficacy analysis will depend on positivity in LJ culture.~* Living within 40 km radius from the nearest sub centre of TRC and willing for attendance as prescribed.~* Likely to remain in the same area for at least one and half years after start of treatment.~* Willing for house visits and surprise checks.~* Willing to participate and give informed consent after going through the terms and conditions of the trial.~Exclusion Criteria:~* Patients with known hypersensitivity to rifampicin~* Pregnancy and lactation at initial presentation~* Major complications like HIV encephalopathy, renal dysfunction (serum creatinine \> 1.5 mg% in the absence of dehydration) or jaundice (serum bilirubin \> 2 mgs% along with SGOT /SGPT elevation \> 2.5 times the upper limit of normal).~* Previous anti-tuberculosis treatment for more than 1 month. Prophylaxis (non-rifampicin containing regimen) will not be considered as prior antituberculosis treatment.~* Moribund, bedridden or unconscious patients.~* Co-morbid conditions like uncontrolled diabetes mellitus, cardiac failure, and malignancy at initial presentation.~* Major psychiatric illness.~* Patients on second line ART, mainly protease inhibitors, at initial presentation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2EHRZ3/4HR3 (Type: ACTIVE_COMPARATOR): Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
- 2EHRZ7/4HR7 (Type: EXPERIMENTAL): Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg daily)
- 2EHRZ7/4HR3 (Type: EXPERIMENTAL): Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight \<60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Gestation up to 63 days~* General good health~* Willingness to provide contact information for follow-up~* Absence of conditions which contraindicate the use of mifepristone and misoprostol for pregnancy termination~Exclusion Criteria:~* Ectopic pregnancy~* Intrauterine device (IUD) in place

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- mifepristone-misoprostol treatment (Type: OTHER): 200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant with histologically confirmed advanced solid tumor.~* Participant must have advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.~* Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.~* Participant must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.~* Participant has archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue available for analysis.~* Participant has adequate bone marrow, renal, and hepatic function.~Exclusion Criteria:~* Participant has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days, or herbal therapy within 7 days prior to the first dose of ABBV-399.~* Participant has known uncontrolled metastases to the central nervous system. Participants with brain metastases are eligible after definitive therapy provided they are asymptomatic off systemic steroids and anticonvulsants for at least 2 weeks prior to first dose of ABBV-399.~* Participant has unresolved clinically significant adverse events \>= Grade 2 from prior anticancer therapy except for alopecia or anemia.~* Participant has had major surgery within 21 days prior to the first dose of ABBV-399.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABBV-399 (Type: EXPERIMENTAL): ABBV-399 via intravenous administration at escalating dose levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic lymphocytic leukemia~* Medically stable, with expected survival of \> 1 year~* Able to understand and willingness to sign a written informed consent~* Able to comply with study procedures~Exclusion Criteria:~* Previously diagnosed primary immunodeficiency~* Additional immunosuppressive states as assessed by the primary or co investigators~* Ongoing therapy with Ig replacement~* Serum IgG \< 500 mg/dL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ig replacement (Type: EXPERIMENTAL): Subjects will receive Hizentra 0.4 mg/kg subq once weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunomodulation by Zinc Supplementation in Children With Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 1 month to 5 years old with clinical and/or radiological diagnosis of pneumonia~* Admitted to the Emergency room at the participant institutions~Exclusion Criteria:~* Prematurity~* Cardiopathy~* Pneumopathy~* Immunosuppression (congenital, chemotherapy or other cause)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Zinc group (Type: EXPERIMENTAL): Zinc sulfate 10 mg in children younger than 1 year old, 20 mg in children older than 1 year old
- Placebo group (Type: PLACEBO_COMPARATOR): Glucose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete